Kurv Yield Premium Strategy Tesla (TSLA) ETF

TSLP

市值 US$1635萬

AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.

Monthly pay dividend equities offer high yields and potential gains, with the top ten broker-estimated MoPay stocks projected to net 27.10%–65.84% by 2027. BCP Investment Corp (BCIC), CION Investment Corp (CION), and Dynex Capital (DX) stand out for both yield and upside, with CION forecasted to deliver a 45.69% net gain. Thirty 'IDEAL' MoPay equities are highlighted for safer dividends, combining positive one-year returns, free-cash-flow yields above dividend yields, and dividends from $1K invested exceeding share price.

March's top-yielding monthly pay (MoPay) equities offer annual dividends from $1K invested exceeding their share price, presenting volatile but potentially lucrative opportunities. Analyst estimates suggest the top 10 MoPay stocks could deliver average net gains of 35.12% by March 2027, with risk/volatility 25% below the market. Stellus Capital Investment (SCM), CION Investment (CION), and PennantPark Floating Rate Capital (PFLT) lead both by yield and price upside, reinforcing the yield-based 'dogcatcher' strategy.

High-yield ETFs provide investors with avenues to compensate for capital losses, if they occur at all.

Tesla shares hit an all-time high. Several analysts raised price targets.

SAN FRANCISCO--(BUSINESS WIRE)--Kurv Investment Management, an ETF provider of tax-efficient, institutional-grade investment strategies, announces the successful reorganization of its Yield Premium Suite ETFs into the Kurv ETF Trust. This transition marks a significant milestone in the company's growth and operational evolution. The Yield Premium Suite includes: Kurv Yield Premium Strategy Amazon (AMZN) ETF Kurv Yield Premium Strategy Apple (AAPL) ETF Kurv Yield Premium Strategy Google (GOOGL).

SAN FRANCISCO--(BUSINESS WIRE)--Kurv Announces Special Distributions.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA).